Key Highlights

  • Revenue for the three months ended September 30, 2026 fell 9.03% to USD 380,216 from USD 417,979, while gross Margin slipped to 25.48% from 34.71% a year earlier.
  • The nine-month net loss reached USD 5,056,270 against USD 2,431,050 a year earlier, as sales, general and administrative costs rose to USD 4,007,461 from USD 2,430,134.
  • Cash and equivalents stood at USD 3,633,711 at September 30, 2026, helped by USD 6,000,000 of series E convertible preferred proceeds raised during the nine months.
  • Management says recurring losses and two Nasdaq deficiencies, covering stock price and stockholders' equity, raise substantial doubt about the company's ability to continue as a going concern.

Quarterly Sales Slip as Costs Climb

20/20 Biolabs (NASDAQ:AIDX) filed its Quarterly Report on November 16, 2026, showing third-quarter Revenue of USD 380,216, down USD 37,763 from the prior-year quarter. The company develops AI-powered, laboratory-based blood tests for early detection of cancers and chronic diseases, sold under the OneTest Brand and run in its accredited laboratory in Gaithersburg, Maryland. OneTest sales eased 2.17% to USD 352,895, which management ties to delays in rolling out cancer screening programs for fire departments outside Maryland. BioCheck, a legacy powder-screening kit, fell 24.33% to USD 27,321, and CLIAx contributed nothing against USD 21,139 a year earlier because of reduced services to its client. Cost of revenues rose 3.82% to USD 283,343, leaving Gross Profit at USD 96,873.

Nine-Month Loss More Than Doubles

Operating expenses for the quarter reached USD 1,486,770, up from USD 945,239, and the operating loss widened to USD 1,389,897 from USD 800,173. Net loss for the quarter was USD 1,375,091 versus USD 825,539. Public company expenses, including officer salary, stock option expense, professional fees and Investor relations fees, drove much of the increase. Over nine months, revenue was USD 1,464,162 against USD 1,506,859, while the net loss rose to USD 5,056,270. Other expense included USD 539,253 of interest expense, a USD 148,766 loss on the change in Fair Value of a Warrant Liability and a USD 326,595 loss on issuance of a convertible note.

Going-Concern Doubt and Nasdaq Deficiencies

Net cash used in Operating Activities was USD 2,806,849 for the nine months, up from USD 1,408,053 a year earlier, while financing brought in USD 5,427,427, mainly from series E convertible preferred stock sold to an investor under a purchase agreement of up to USD 40,000,000. The company reports a Nasdaq deficiency on stock price and another on stockholders' equity. If delisting occurs, the series E preferred would default and become a current liability. Planned remedies include Equity raises and reverse stock splits, which need a stockholder vote. Management says its bankers may not be able to raise the amounts needed, and without new funds current resources would not cover planned spending for the next 12 months.

Where Things Stand

The loss widened because costs grew while sales fell. Selling, general and administrative expenses rose by roughly two thirds in the quarter, and gross margin narrowed as fixed laboratory costs were spread over lower revenue. 20/20 Biolabs ended the period with USD 3,633,711 of cash, but management still flags going-concern doubt. The next markers are any Reverse Stock Split vote, further series E closings and progress on the two Nasdaq deficiencies, all of which determine how much dilution shareholders may face.